Journals / Glokom Katarakt / 2011 / Cilt: 6 - Sayı: 4

Cyclosporine a treatment in a dry eye case with flamentary keratitis

Flamenter keratitli kuru göz olgusunda siklosporin a tedavisi

Pages
263–265
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Flamentary keratitis was regressed obviously and signs and symptoms of the patient were improved.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nowadays dry eye is a very common disease.
📊
Key Findings & Data:Dry eye patients that can be classified as mild, moderate, severe relieve by artificial tear usage for a while.
💡
Conclusion & Impact:Flamentary keratitis was regressed obviously and signs and symptoms of the patient were improved.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nowadays dry eye is a very common disease. Most of the patients examined in the ophtalmology clinics have dry eye complaints. Dry eye patients that can be classified as mild, moderate, severe relieve by artificial tear usage for a while. Nevertheless this treatment is not a permanent solution, also in some severe patients it is not sufficient alone. In our case 55 years old male patient was a severe dry eye patient who progressed to flamentary keratitis. Previously he used many topical treatments but had no benefit and disease progressed. Topical cyclosporine A together with artificial tear was used for the patient. Flamentary keratitis was regressed obviously and signs and symptoms of the patient were improved.

Özet

Kuru göz günümüzde oldukça yaygın bir rahatsızlıktır. Göz polikliniğinde muayene edilen hastaların büyük çoğunluğunda kuru göz şikayetleri mevcuttur. Hafif, orta, ağır şeklinde sınıflandırılabilen kuru gözlü hastaların bir kısmı suni gözyaşı kullanımı ile bir süre rahatlamaktadır. Bu tedavi kalıcı bir çözüm olmamakla birlikte bazı ağır hastalarda tek başına yeterli değildir. Olgumuz 55 yaşında erkek hasta olup flamenter keratite ilerlemiş ağır kuru göz hastasıdır. Daha önce çeşitli topikal ilaç tedavileri kullanmış ancak yarar sağlanamamış ve hastalık ilerlemiştir. Hastaya suni gözyaşı ile birlikte topikal siklosporin A (CsA) tedavisi uygulandı. Flamenter keratit belirgin bir şekilde geriledi, hastanın bulgu ve semptomlarında düzelme sağlandı.

🔖

Cite This Article

EVŞEN, S., ARI, Ş. (2011). Cyclosporine a treatment in a dry eye case with flamentary keratitis. Glokom Katarakt, Cilt: 6 - Sayı: 4, 263–265. https://ajindex.com/articles/226512

References (14)

  1. Yüksel B, Bozdağ B, Acar M, et al.: Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. Eur J Ophthalmol. 2010; 20:675-659
  2. De Paiva CS, Pflugfelder SC.: Rationale for anti-inflamatory therapy in the dry eye syndrome. Arq. Bras. Oftalmol. 2008;71:89-95
  3. Sahli E, Hoşal BM, Zilelioğlu G, et al.: The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea. 2010;29:1412- 1416
  4. Dastjerdi MH, Hamrah P, Dana R.: High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28:1091-1096
  5. Gündüz K, Ozdemir O.: Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome.Acta Ophthalmol. 1994;72:438-442
  6. Strong B, Farley W,Stern ME, et al.: Topical cyclosporine inhibits conjunctival epitelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80-85
  7. Perry HD, Doshi-Carnavale S, Donnenfeld ED et al.: Efficacy of commercially available topical cyclosporine A in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171-175
  8. Moon JW, Lee HJ, Shin KC et al.: Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in the patients with dry eye. Korean J Ophthalmol. 2009;54:321-338
  9. Stevenson D, Tauber J, Reis BL.: The cyclosporine A phase 2 study group efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye disease a dose-ranging, randomized trial. Ophthalmology. 2000;107:967-974
  10. Sall K, Stevenson OD, Mundorf TK, et al.: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in the moderate tosevere dry eye disease. Ophthalmology. 2000;107:631-639
  11. Wilson SE, Perry HD.: Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114:76-79
  12. Barber LD, Pflufelder SC, Tauber J, et al.:. Phase Ⅲ safety evaluation of cyclosporine 0,1% ophthalmis emulsion administered twice daily to dry eye disease patients for up ot 3 years. Ophthalmology. 2005;112:1790-1794
  13. Perry HD, Solomon R, Donnenfeld ED et al.: Evaluation of topical cyclosporine fort he treatment of the dry eye disease. Arch.Ophthalmol. 2008;126:1046-1050
  14. Kaçmaz RO, Kempen JH, Newcomb C, et al.: Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;1